Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Management of IgA vasculitis nephritis (Henoch-Schonlein purpura nephritis) in Children

  • Namgoong, Meekyng (Department of Pediatrics, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine)
  • Received : 2020.03.19
  • Accepted : 2020.04.04
  • Published : 2020.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Immunoglobulin (Ig)A vasculitis nephritis (IgAVN), also referred to as Henoch-Schönlein purpura nephritis, is a relatively benign disease in children. However, two 24-year European cohort studies have reported high sustained rates of hypertension, severe proteinuria, and renal dysfunction in patients with IgAVN. Notably, the incidence and exacerbation rates of proteinuria, hypertension, and renal dysfunction during pregnancy were high even in women who recovered from IgAVN before pregnancy. Patients with IgAVN need lifelong care. Trials have been performed to investigate early biomarkers and genes associated with poor prognosis to identify high-risk patients in whom IgAVN may progress to severe renal disease. Urinary IgA/cr, IgM/cr levels, and HLAB35 and angiotensinogen gene expression were shown to be predictors of progression of IgAVN to severe renal dysfunction. The 2019 Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative group published guidelines for pediatric IgAVN, following the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines established in 2012. Compared with the KDIGO guidelines, the SHARE guidelines recommend earlier corticosteroid administration in cases of mild proteinuria (>0.5 g/d). Clinical trials of targeted budesonide delivery to the distal ileum, monoclonal antibody targeting C5, eculizumab and anti-CD20 monoclonal antibody administration, among others are currently underway in patients with IgA nephropathy. It is expected that newer therapeutic agents would become available for IgAVN in the near future. This review summarizes IgAVN with emphasis on recently published literature, including possible preventive strategies, predictive biomarkers for progression of IgAVN, and various treatments.

Keywords

References

  1. Pillebout E, Jamin A, Ayari H, Housset P, Pierre M, Sauvaget V, et al. Biomarkers of IgA vasculitis nephritis in children. PLoS One 2017;12:e0188718. https://doi.org/10.1371/journal.pone.0188718
  2. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill consensus conference nomenclature of Vasculitis. Arthritis Rheum 2013;65:1-11.
  3. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthritis Rheum 1990;33:1114-21.
  4. Ozen S1, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010;69:798-806. https://doi.org/10.1136/ard.2009.116657
  5. Jung DY, Kwon YR, Yu MH, Namgoong MK. Cinical Features and Prognosis of Henoch-Schonlein Purpura in Children and Adults: A 13-Year Retrospective Study at a Single Centre. Child Kidney Dis 2017;21:61-8. https://doi.org/10.3339/jkspn.2017.21.2.61
  6. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Arch Dis Child 2010;95:877-82. https://doi.org/10.1136/adc.2009.182394
  7. Saulsbury FT. Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature. Medicine(Baltimore) 1999;78:395-409. https://doi.org/10.1097/00005792-199911000-00005
  8. Calvino MC, Llorca J, Garcia-Porrua C, Fernandez-Iglesias JL, Rodriguez-Ledo P, Gonzalez-Gay MA. Henoch-Schonlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine (Baltimore). 2001;80:279-90. https://doi.org/10.1097/00005792-200109000-00001
  9. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005;90:16-20.
  10. Wang H, Das L Hoh SF, Gao X, Book YX, Arkachaisri T. Urinalysis Monitoring In Children With Henoch-Schonlein Purpura: Is It Time To Revise? Int J Rheum Dis 2019;22:1271-7. https://doi.org/10.1111/1756-185X.13552
  11. de Almeida JL, Campos LM, Paim LB, Leone C, Koch VH, Silva CA. Renal involvement in Henoch-Schonlein purpura: a multivariate analysis of initial prognostic factors. J Pediatr 2007;83:259-66. https://doi.org/10.2223/JPED.1638
  12. Alfredo CS, Nunes NA, Len CA, Barbosa CM, Terreri MT, Hilario MO. Henoch-Schonlein purpura: recurrence and chronicity. J Pediatr 2007;83:177-80. https://doi.org/10.1590/S0021-75572007000200013
  13. Allen AC, Willis FR, Beattie TJ, Feehally J. Abnormal IgA glycosylation in Henoch-Schonlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant 1998;13:930-4. https://doi.org/10.1093/ndt/13.4.930
  14. Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyl-transferase. Proc Natl Acad Sci USA 2002;99:16613-8 https://doi.org/10.1073/pnas.262438199
  15. He X, Zhao P, Kang S, Ding Y, Luan J, Liu Z, et al. C1GALT1 polymorphisms are associated with Henoch-Schonlein purpura nephritis. Pediatr Nephrol 2012;27:1505-9. https://doi.org/10.1007/s00467-012-2178-9
  16. Mahajan V, Singh S, Khullar M, Minz RW. Serum and urine nitric oxide levels in children with Henoch-Schonlein purpura during activity and remission: a study from North India. Rheumatol Int 2009;29:1069-72. https://doi.org/10.1007/s00296-008-0800-8
  17. Jiang J, Duan W, Shang X, Wang H, Gao Y, Tian P, et al. Inducible nitric oxide synthase gene polymorphisms are associated with a risk of nephritis in Henoch-Schonlein purpura children. Eur J Pediatr 2017;176:1035-45. https://doi.org/10.1007/s00431-017-2945-5
  18. Ozkaya O. Soylemezoglu O. Gonen S. Misirlioglu M. Tuncer S. Kalman S, et al. Renin-angiotensin system gene polymorphisms: association with susceptibility to Henoch-Schonlein purpura and renal involvemene. Clin Rheumatol 2006;25:861-5. https://doi.org/10.1007/s10067-006-0207-4
  19. Amoli MM, Thomson W, Hajeer AH, Calvino MC, Garcia-Porrua C, Ollier WE, et al. Interleukin 8 gene polymorphism is associated with increased risk of nephritis in cutaneous vasculitis. J Rheumatol 2002;29:2367-70.
  20. Nathwani D, Laing RB, Smith CC, Edward N. Recurrent post-infective Henoch-Schonlein syndrome: a genetic influence related to HLA B35? J Infect 1992;25:205-10. https://doi.org/10.1016/0163-4453(92)94127-J
  21. Amoli MM, Thomson W, Hajeer AH, Calvino MC, Garcia-Porrua C, Ollier WE, et al. HLA-B35 association with nephritis in Henoch- Schonlein purpura. J Rheumatol 2002;29:948-9.
  22. Zhou TB, Ou C, Qin YH, Luo W. A meta-analysis of the association between angiotensin-converting enzyme insertion/deletion gene polymorphism and Henoch-Schonlein purpura nephritis risk in Asian children. Clin Exp Rheumatol 2012;30:315-6.
  23. He X, Yin W, Ding Y, Cui SJ3, Luan J4, Zhao P1, et al. Higher serum angiotensinogen is an indicator of IgA vasculitis with nephritis revealed by comparative proteomes analysis. PLoS One 2015;10:e0130536. https://doi.org/10.1371/journal.pone.0130536
  24. Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, et al. Early prednisone therapy in Henoch-Schonlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr 2006;149:241-7. https://doi.org/10.1016/j.jpeds.2006.03.024
  25. Huber AM, King J, McLaine P, Klassen T, Pothos M. A randomized, placebo-controlled trial of prednisone in early Henoch Schonlein purpura. BMC Med 2004;2:7-13. https://doi.org/10.1186/1741-7015-2-7
  26. Dudley J, Smith G, Llewelyn-Edwards A, Bayliss K, Pike K, Tizard J. Randomized, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP). Arch Dis Child 2013;98:756-63. https://doi.org/10.1136/archdischild-2013-303642
  27. Hahn D, Hodson EM, Willis NS, Craig JC. Interventions for preventing and treating kidney disease in Henoch-Schonlein Purpura (HSP). Cochrane Database Syst Rev 2015;7:Cd005128.
  28. Coppo R, Mazzucco G, Cagnoli L, Lupo A, Schena FP. Long-term prognosis of Henoch-Schonlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schonlein purpura. Nephrol Dial Transplant 1997;12:2277-83. https://doi.org/10.1093/ndt/12.11.2277
  29. Goldstein AR, White RH, Akuse R, Chantler C. Long-term followup of childhood Henoch-Schonlein nephritis. Lancet 1992;339:280-2. https://doi.org/10.1016/0140-6736(92)91341-5
  30. Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 yearsafter childhood Henoch-Schonlein purpura: a retrospective cohort study. Lancet 2002;360:666-70. https://doi.org/10.1016/S0140-6736(02)09835-5
  31. Butani L, Morgenstern BZ. Long-term outcome in children after Henoch-Schonlein purpura nephritis. Clin Pediatr (Phila) 2007;46:505-11. https://doi.org/10.1177/0009922806298896
  32. Fogazzi GB, Pasquali S, Moriggi M, Casanova S, Damilano I, Mihatsch MJ, et al. Long-term outcome of Schonlein-Henoch nephritis in the adult. Clin Nephrol 1989;31:60-6.
  33. Huang X, Wu J, Wu XM, Hao YX, Zeng CH, Liu ZH, et al. Significance of histological crescent formation in patients with IgA vasculitis (Henoch-Schonlein purpura)-related nephritis: a cohort in the adult Chinese population. BMC Nephrol 2018;22:334-43.
  34. Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D. Henoch-Schonlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol 2002;13:1271-8. https://doi.org/10.1097/01.ASN.0000013883.99976.22
  35. Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schonlein-Henoch purpura nephritis. Pediatr Nephrol 1998;12:238-43. https://doi.org/10.1007/s004670050446
  36. Hattori M, Ito K, Konomoto T, Kawaguchi H, Yoshioka T, Khono M: Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schonlein purpura nephritis in children. Am J Kidney Dis 1993;33:427-33. https://doi.org/10.1016/S0272-6386(99)70178-2
  37. Shenoy M, Ognjanovic MV, Coulthard MG: Treating severe Henoch-Schonlein and IgA nephritis with plasmapheresis alone. Pediatr Nephrol 2007;22:1167-71. https://doi.org/10.1007/s00467-007-0498-y
  38. Lan HY, Nikolic-Paterson DJ, Mu W, Vannice JL, Atkins RC: Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. Kidney Int 1995;47:1303-9. https://doi.org/10.1038/ki.1995.185
  39. Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD: Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 2005;67:1812-20. https://doi.org/10.1111/j.1523-1755.2005.00279.x
  40. Lopez-Mejias R, Castaneda S, Genre F, Remuzgo-Martinez S, Carmona FD, Llorca J, et al. Genetics of immunoglobulin-A vasculitis (Henoch-Schonlein purpura): an updated review. Autoimmun Rev 2018;17:301-15. https://doi.org/10.1016/j.autrev.2017.11.024
  41. Kung JT, Colognori D, Lee JT. Long noncoding RNAs: Past, present, and future. Genetics 2013;193:651-69. https://doi.org/10.1534/genetics.112.146704
  42. Kapusta A, Feschotte C. Volatile evolution of long noncoding RNA repertoires: Mechanisms and biological implications. Trends Genet 2014;30:439-52. https://doi.org/10.1016/j.tig.2014.08.004
  43. Pang S, Lv J, Wang S, Yang G, Ding X, Zhang J. Differential expression of long non-coding RNA and mRNA in children with Henoch-Schonlein purpura nephritis. Exp Ther Med 2019;17:621-32. https://doi.org/10.3892/etm.2018.7038
  44. Kidney Disease: Improving Global Outcomes. Chapter 11: Henoch-Schonlein purpura nephritis. Kidney Int Suppl(2011) 2012;2:218-20. https://doi.org/10.1038/kisup.2012.24
  45. Emancipator SN (1993) Primary and secondary forms of IgA nephritis and Schonlein-Henoch syndrome. In: Heptinstall RH (ed) Pathology of the kidney. Little Brown, London, pp 389-476.
  46. Davin JC, Ten Berge IJ, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schonlein purpura nephritis? Kidney Int 2001;59:823-4. https://doi.org/10.1046/j.1523-1755.2001.059003823.x
  47. Andersen RF, Rubak S, Jespersen B, Rittig S. Early high-dose immunosuppression in Henoch-Schonlein nephrotic syndrome may improve outcome. Scand J Urol Nephrol 2009;43:409-15. https://doi.org/10.3109/00365590903164480
  48. Davin JC, Coppo R. Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Schonlein purpura nephritis. Pediatr Nephrol 2013;28:1897-903. https://doi.org/10.1007/s00467-013-2550-4
  49. 2018 - KDIGO Clinical Practice Guideline for Glomerulonephritis. KDIGO GN Guideline update - Evidence summary. (https://kdigo.org/wp-content/uploads/2018/08/Chap-12-Lupus-nephritisevidence-summary_final_profiles.pdf).
  50. Tarshish P, Bernstein J, Edelmann CM Jr. Henoch-Schonlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol 2004;19:51-6. https://doi.org/10.1007/s00467-003-1315-x
  51. Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. STOP-IgAN Investigators. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med 2015;373:2225-36. https://doi.org/10.1056/NEJMoa1415463
  52. Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 2017;318:432-42. https://doi.org/10.1001/jama.2017.9362
  53. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kid Int 2019;95:268-80. https://doi.org/10.1016/j.kint.2018.10.018
  54. Ozen S, Marks SD, Brogan P, Groot N, de Graeff N, Avcin T, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology 2019;58:1607-16 https://doi.org/10.1093/rheumatology/kez041
  55. Niaudet P, Appel GB, Hunder GG. IgA vasculitis (Henoch-Schonlein purpura): Renal manifestations [Internet]. UpToDate:[cited 2019 Sep 10]. Available from: https://www.uptodate.com/contents/iga-vasculitis-henoch-schonlein-purpura-renal-manifestations.
  56. Smith AC, Molyneux K, Feehally J, Barratt J. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol 2006;17:3520-8. https://doi.org/10.1681/ASN.2006060658
  57. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, et al. Genomewide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011;43: 321-7. https://doi.org/10.1038/ng.787
  58. Block GA, Whitaker S. Maintenance of remission following completion of OMS721 treatment in patients with IgA nephropathy (IGAN). Abstract SA-PO278. J Am Soc Nephrol 2017;28:749-50.
  59. Fellstrom BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy(NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 2017;389:2117-27. https://doi.org/10.1016/S0140-6736(17)30550-0
  60. Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int 2018;93:700-5. https://doi.org/10.1016/j.kint.2017.10.019
  61. Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol 2015;26:1503-12. https://doi.org/10.1681/ASN.2014101000
  62. Hisano S, Matsushita M, Fujita T, Iwasaki H: Activation of the lectin complement pathway in Henoch-Schonlein purpura nephritis. Am J Kidney Dis 2005;45:295-302. https://doi.org/10.1053/j.ajkd.2004.10.020
  63. Abou-Ragheb HH, Williams AJ, Brown CB, Milford-Ward A. Plasma levels of the anaphylatoxins C3a and C4a in patients with IgA nephropathy/Henoch-Schonlein nephritis. Nephron 1992;62:22-6. https://doi.org/10.1159/000186989
  64. Omeros. FDA grants orphan drug designation to Omeros' OMS721 for treatment of IgA nephropathy. Omeros. 2017 http://investor.omeros.com/phoenix.zhtml?c=219263&p=irol-newsArticle_Print&ID=2292002.
  65. Espinosa M, Ortega R, Sanchez M, Segarra A, Salcedo MT, Gonzalez F, et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol 2014;9:897-904. https://doi.org/10.2215/CJN.09710913
  66. Crayne CB, Eloseily E, Mannion ML, Azerf SP, Weiser P, Beukelman T, et al. Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J 2018;16:71. https://doi.org/10.1186/s12969-018-0285-2
  67. Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. J Am Soc Nephrol 2017;28:1306-13. https://doi.org/10.1681/ASN.2016060640
  68. Tian M, Liu C. Heparin calcium treated Henoch-Schonlein purpura nephritis in children through inhibiting hyperfibrinolysis. Ren Fail 2015;37:1100-4. https://doi.org/10.3109/0886022X.2015.1061668
  69. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 1987;32:78-83. https://doi.org/10.1038/ki.1987.174
  70. Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991;39:1267-73. https://doi.org/10.1038/ki.1991.160
  71. Ninchoji T, Kaito H, Nozu K, Hashimura Y, Kanda K, Kamioka I, et al. Treatment strategies for Henoch-Schonlein purpura nephritis by histological and clinical severity. Pediatr Nephrol 2011;26:563-9. https://doi.org/10.1007/s00467-010-1741-5
  72. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, et al. Igace: a placebo-controlled, randomized trial of angiotensinconverting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007;18:1880-8. https://doi.org/10.1681/ASN.2006040347
  73. Maeba S, Ichiyama T, Ueno Y, Makata H, Matsubara T, Furukawa S. Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. Ann Allergy Asthma Immunol 2005;94:670-4. https://doi.org/10.1016/S1081-1206(10)61326-9
  74. Wu SH, Liao PY, Chen XQ, Yin PL, Dong L. Add-on therapy with montelukast in the treatment of Henoch-Schonlein purpura. Pediatr Int 2014;56:315-22. https://doi.org/10.1111/ped.12271
  75. Neufeld M, Molyneux K, Pappelbaum KI, Mayer-Hain S, von Hodenberg C, Ehrchen J, et al. Galactose deficient IgA1 (GD-IgA1) in skin and serum from patients with skin-limited and systemic IgA Vasculitis. J Am Acad Dermatol 2019;19:30443-8.
  76. Vuong MT, Hahn-Zoric M, Lundberg S, Gunnarsson I, van Kooten C, Wramner L, et al. Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int 2010;78:1281-7. https://doi.org/10.1038/ki.2010.314
  77. Papista C, Lechner S, Ben Mkaddem S, LeStang MB, Abbad L, Bex-Coudrat J, et al. Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction. Kidney Int 2015;88:276-85. https://doi.org/10.1038/ki.2015.94
  78. Landecho MF, Ros NF, Alegre F, Idoate MA, Lucena JF. Henoch-Schonlein purpura associated with celiac disease. J Am Acad Dermatol 2011;64:e120-1. https://doi.org/10.1016/j.jaad.2010.10.017
  79. Legendre P, Regent A, Thiebault M, Mouthon L. Anti-endothelial cell antibodies in vasculitis: a systematic review. Autoimmun Rev 2017;16:146-53. https://doi.org/10.1016/j.autrev.2016.12.012
  80. Fujieda M, Oishi N, Naruse K, Hashizume M, Nishiya K, Kurashige T, et al. Soluble thrombomodulin and antibodies to bovine glomerular endothelial cells in patients with Henoch-Schonlein purpura. Arch Dis Child 1998;78:240-4. https://doi.org/10.1136/adc.78.3.240
  81. Yang YH, Wang SJ, Chuang YH, Lin YT, Chiang BL. The level of IgA antibodies to human umbilical vein endothelial cells can be enhanced by $TNF-{\alpha}$ treatment in children with Henoch-Schonlein purpura. Clin Exp Immunol 2002;130:352-7. https://doi.org/10.1046/j.1365-2249.2002.01964.x
  82. Inoue CN, Matsutani S, Ishidoya M, Homma R, Chiba Y, Nagasaka T. Periodontal and ENT therapy in the treatment of pediatric henoch-schonlein purpura and IgA nephropathy. Adv Otorhinolaryngol 2011;72:53-6.